Lek Boasts 2006 Revenues of EUR 721m
Ljubljana, 19 January - Pharmaceutical company Lek, a subsidiary of Novartis's generic arm Sandoz, posted sales of EUR 721m for 2006, an increase of 33% over the year before. Lek said profits grew significantly, but it did not disclose the figures in Friday's press release.
The rest of this news item is available to subscribers.
The news item consists of 759 characters (without spaces) or 151 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.